Related Experiment Videos
[Current approaches to management of patients with mild cognitive impairment]
1Sechenov First Moscow State Medical University, Moscow, Russia.
Abstract:
Mild cognitive impairment (MCI) is an intermediate stage between normal aging and dementia. The prevalence of MCI among elderly people is 12-17% but the risk of progression of cognitive impairment and development of dementia during 5 years is up to 70%. Cerebral vascular diseases and initial stages of neurodegenerative processes are the cause of MCI. Clinical characteristics of MCI depend on the main etiological factor. To decrease the severity of symptoms and prevent the progression of cognitive impairment in MCI patients, pharmacotherapy and non-medication methods, including diet optimization, stimulation of mental and physical activity, are used. Dopaminergic and noradrenergic therapy is most prevalent among pharmacological methods.
Insights
Mild cognitive impairment (MCI) affects 12-17% of elderly individuals, with a high risk of progressing to dementia. Early intervention with pharmacotherapy and lifestyle changes can help manage symptoms and slow cognitive decline.
Area of Science:
- Neurology
- Gerontology
- Cognitive Science
Background:
- Mild cognitive impairment (MCI) represents a critical transitional phase between normal aging and dementia.
- The prevalence of MCI in the elderly population ranges from 12% to 17%.
- A significant risk (up to 70% over 5 years) exists for MCI progression to dementia.
Purpose of the Study:
- To review the causes and clinical characteristics of MCI.
- To outline current therapeutic strategies for managing MCI.
- To highlight the role of pharmacotherapy and non-medication interventions in preventing dementia progression.
Main Methods:
- Literature review of etiological factors and clinical presentations of MCI.
- Analysis of pharmacotherapy options, including dopaminergic and noradrenergic agents.
- Evaluation of non-medication interventions such as diet, mental, and physical activity stimulation.
Main Results:
- MCI etiology is linked to cerebrovascular diseases and early neurodegenerative processes.
- Clinical manifestations of MCI vary based on the underlying cause.
- Pharmacological and non-pharmacological interventions are employed to mitigate MCI symptoms and progression.
Conclusions:
- Effective management of MCI involves addressing its specific etiological factors.
- A combination of pharmacotherapy and lifestyle modifications is crucial for preventing dementia.
- Dopaminergic and noradrenergic therapies represent common pharmacological approaches for MCI treatment.